Strategy pays off for Bard

Article Excerpt

C.R. BARD INC. $195 (New York symbol BCR; Conservative Growth Portfolio, Consumer sector; Shares outstanding: 74.2 million; Market cap: $14.5 billion; Price-to-sales ratio: 4.2; Dividend yield: 0.5%; TSINetwork Rating: Above Average; www.crbard.com) is benefiting from its growth strategy, which involves selling lessprofitable businesses and buying other medical-device makers. A good example is its 2011 purchase of Lutonix, which has developed a drug-coated balloon for treating clogged leg arteries. In the three months ended June 30, 2015, Bard’s earnings rose 7.9%, to $154.3 million from $143.0 million a year earlier. Per-share profits gained 10.2%, to $2.27 from $2.06. Sales gained 4.0%, to $859.8 million from $827.1 million. Bard gets two-thirds of its sales from customers outside of the U.S. If you exclude the negative impact of currency-exchange rates, its sales rose 8%. The stock trades at 21.6 times the $9.02 a share Bard will probably earn in 2015. That’s a reasonable multiple for the company, which spends 7% of its revenue…